Innovent Biologics (1801) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business Overview and Strategic Achievements

• Achieved over $1 billion in sales in 2024, with more than 50% year-over-year revenue growth and robust commercial and R&D capabilities.

• Celebrated 14th product approval, with over 20 assets in development and rapid portfolio expansion.

• Formed strategic partnerships with Roche and Eli Lilly, supporting innovation and commercialization.

• Focused on biologics, investing in monoclonal antibodies, bispecifics, ADCs, and cell therapy, leveraging a fully integrated biopharma platform.

• Strong talent base and 140KL manufacturing capacity support growth ambitions.

Oncology Pipeline and Technology Innovation

• Commercialized 11 oncology products, with three among China's top 10 fastest-growing oncology drugs.

• Tyvyt® leads PD-(L)1 therapies in China; Sintilimab leads in patient and value share among 23 PD-1 products.

• Advanced ADC platform with multiple clinical assets, including phase III trials for gastric and pancreatic cancers.

• In-house ADC technology reduces toxicity by over 80% and is licensed to Roche in a $1 billion+ deal, with IBI3009 licensed globally for SCLC.

• Breakthrough designation received for pancreatic cancer ADC, with plans for registration trial.

Immuno-oncology and Resistance Solutions

• Developed novel PD-1/IL-2 fusion molecule to address resistance in IO failures and cold tumors.

• Achieved 30-40% ORR in lung cancer IO failures and over 15% ORR in colorectal cancer.

• Combination therapy in first-line settings reached 70% ORR, indicating potential to transform IO treatment.